PhotonPharma

Executive Summary

PhotonPharma Inc. is a preclinical-stage biotechnology company pioneering light-activated personalized therapeutics for cancer treatment. Its lead platform, Innocell™, is an autologous vaccine designed to train a patient's immune system to recognize and destroy their specific cancer cells. The company is initially targeting recurrent ovarian cancer, a significant unmet medical need, and is preparing to advance into Phase 1 clinical studies. Founded in 2019 and based in San Francisco, PhotonPharma represents a novel approach in the cell and gene therapy space, leveraging light activation to enhance specificity and potency. Given its early stage, the company faces substantial clinical and regulatory risks, but if successful, its personalized platform could address multiple oncology indications. The lack of disclosed funding or revenue underscores the need for external capital to advance development. With a first-in-human trial imminent, PhotonPharma is at a critical inflection point, with near-term milestones likely to determine its trajectory. Conviction score: 45.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 Clinical Trial for Recurrent Ovarian Cancer60% success
• Q4 2026Interim Safety and Tolerability Data Release40% success
• TBDStrategic Partnership or Funding Round30% success